PatientsVille.com Logo


Innohep Medical Research Studies

Up-to-date List of Innohep Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Innohep Medical Research Studies

Rank Status Study
1 Not yet recruiting Use of Tinzaparin for Anticoagulation in Hemodialysis
Condition: Kidney Failure, Chronic
Interventions: Drug: Tinzaparin;   Drug: Unfractionated Heparin;   Drug: Placebo (for Tinzaparin);   Drug: Placebo (for Unfractionated Heparin)
Outcome Measures: Rate of major, clinically important non-major or minor bleeding;   Clotting in extracorporeal dialysis circuit
2 Recruiting Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
Conditions: Venous Thrombosis;   Pulmonary Embolism
Intervention: Drug: Tinzaparin
Outcome Measure: Anti-Xa level measured on any two of Days 3, 5 or 7 of treatment
3 Recruiting Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colon Cancer
Condition: Adenocarcinoma of the Colon
Intervention: Drug: Tinzaparin
Outcome Measures: Disease Free Survival;   Overall Survival;   Venous Thromboembolism events;   Major surgical site bleeding events;   Major bleeding events (not including the surgical site);   • Clinically relevant bleeding events prior to surgery and during the • Clinically relevant bleeding events;   Transfusion requirements;   Correlative endpoints;   Other post-operative (day 0 - day 28) complications
4 Recruiting Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
Conditions: Deep Venous Thrombosis;   Pulmonary Embolism
Interventions: Drug: Low dose nadroparin;   Drug: Intermediate dose nadroparin;   Drug: Low dose enoxaparin;   Drug: Intermediate dose enoxaparin;   Drug: Low dose dalteparin;   Drug: Intermediate dose dalteparin;   Drug: Fixed low dose tinzaparin;   Drug: Intermediate dose tinzaparin
Outcome Measures: Symptomatic deep venous thrombosis;   Symptomatic pulmonary embolism
5 Unknown  Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?
Condition: Fetal Growth Retardation
Interventions: Drug: Innohep (Tinzaparin);   Drug: tinzaparin
Outcome Measures: birth weight;   maternal morbidity
6 Unknown  Venous Thromboembolism Prophylaxis Post Cesarean Section
Conditions: Bleeding;   Venous Thromboembolism
Interventions: Drug: TINZAPARIN;   Drug: PLACEBO
Outcome Measures: Deep Vein Thrombosis;   symptomatic DVT and bleeding
7 Not yet recruiting Anticoagulation Length in Cancer Associated Thrombosis
Conditions: Cancer;   Thrombosis;   Venous Thromboembolism;   Deep Vein Thrombosis;   Pulmonary Embolus
Intervention: Drug: Low Molecular Weight Heparin (LMWH)
Outcome Measures: Number of eligible and recruited patients (target recruitment rate of 30% of eligible patients) over 12 months, and proportion of participants with recurrent VTEs during follow-up.;   Completion of trial protocol;   Quality of life;   Symptom assessment during the study;   Attitudes of clinicians and patients to extended treatment with LMWH
8 Recruiting Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)
Conditions: Lung Cancer;   Non Small Cell Lung Cancer
Intervention: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks
Outcome Measures: Overall 3-year mortality;   Major bleeding time;   Symptomatic venous thromboembolic events;   Cancer related mortality;   Disease free survival
9 Recruiting Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
Condition: Unsuspected Pulmonary Embolism
Intervention: Drug: Heparin, fondaparinux, vitamin-K antagonists, aspirin
Outcome Measures: Recurrent (symptomatic) vein thromboembolism, including pulmonary embolism and deep vein thrombosis;   Major, clinically relevant non-major bleeding, and minor bleeding
10 Recruiting Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome
Conditions: Recurrent Pregnancy Losses;   Positive Anti Phospholipid Syndrome
Intervention: Drug: low molecular weight heparin (enoxeparine)
Outcome Measure: Pregnancy continuation beyond twelve weeks gestation
11 Recruiting Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
Conditions: Venous Thromboembolism;   Neoplasms
Interventions: Drug: low molecular weight heparin;   Drug: vitamin K antagonists
Outcome Measures: Symptomatic recurrent VTE, i.e. the composite of recurrent deep venous thrombosis and fatal or non-fatal pulmonary embolism;   All clinically relevant bleeding (i.e. major bleeding and other clinically relevant non-major bleeding);   all-cause mortality
12 Not yet recruiting Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
Conditions: Venous Thromboembolism;   Deep Vein Thrombosis;   Pulmonary Embolism
Outcome Measures: Symptomatic venous thromboembolism;   Symptomatic recurrent venous thromboembolism;   Symptomatic recurrent pulmonary embolism;   Thrombocytopenia or heparin-induced thrombocytopenia (HIT);   Symptomatic osteoporosis;   Other complications;   Pregnancy complications and outcomes;   Fetal anomalies;   Major and minor bleeding
13 Recruiting Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage
Condition: Major hæmorrhage
Interventions: Drug: UFH Early group;   Drug: UFH Late group
Outcome Measures: The main criterion in this study is the cumulated incidence of mortality, hæmorrhage recurrence and thromboembolic complications at 1 month;   -We will evaluate the risk/benefit balance of early versus late resumption of anticoagulant treatment,
14 Recruiting Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Conditions: Deep Vein Thrombosis;   Venous Thrombosis;   Postphlebitic Syndrome;   Venous Thromboembolism;   Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Outcome Measures: Cumulative incidence of Post-Thrombotic Syndrome (Villalta Scale);   Severity of post thrombotic syndrome, resolution of presenting DVT symptoms, the prevalence of valvular reflux and residual thrombus, the degree of clot lysis, and cost-effectiveness.;   Major bleeding, symptomatic pulmonary embolism, recurrent venous thromboembolism, and death

These studies may lead to new treatments and are adding insight into Innohep etiology and treatment.

A major focus of Innohep research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Innohep